PD41-11 EVALUATION OF A BREAST CANCER SPECIFIC CIRCULATING TUMOR CELL (CTC) PLATFORM IN DIFFERENT STAGES OF BLADDER CANCER REFLECTS A COMMON MOLECULAR BACKGROUND
2015-03-31

You have accessJournal of UrologyBladder Cancer: Staging1 Apr 2015PD41-11 EVALUATION OF A BREAST CANCER SPECIFIC CIRCULATING TUMOR CELL (CTC) PLATFORM IN DIFFERENT STAGES OF BLADDER CANCER REFLECTS A COMMON MOLECULAR BACKGROUND Tilman Todenhöfer, Jörg Hennenlotter, Natalie Dorner, Gunthild Beger, Valentina Gerber, Georgios Gakis, Simone Bier, Steffen Rausch, Johannes Mischinger, Stefan Aufderklamm, Natalie Feniuk, Doreen Schellbach, Arnulf Stenzl, and Christian Schwentner Tilman TodenhöferTilman Todenhöfer More articles by this author , Jörg HennenlotterJörg Hennenlotter More articles by this author , Natalie DornerNatalie Dorner More articles by this author , Gunthild BegerGunthild Beger More articles by this author , Valentina GerberValentina Gerber More articles by this author , Georgios GakisGeorgios Gakis More articles by this author , Simone BierSimone Bier More articles by this author , Steffen RauschSteffen Rausch More articles by this author , Johannes MischingerJohannes Mischinger More articles by this author , Stefan AufderklammStefan Aufderklamm More articles by this author , Natalie FeniukNatalie Feniuk More articles by this author , Doreen SchellbachDoreen Schellbach More articles by this author , Arnulf StenzlArnulf Stenzl More articles by this author , and Christian SchwentnerChristian Schwentner More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.2419AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Circulating tumor cells (CTC) have been shown to be present in a significant proportion of patients with solid tumors. To date, no system has been approved for detection of circulating tumor cells in bladder cancer (BC). The Adnatest© system combines immunomagnetic enrichment of epithelial cells with polymerase chain reaction (PCR) for cancer specific transcripts. It has been demonstrated to enable characterization of CTCs and prediction of treatment response in prostate cancer patients (Antonarakis et al., New England Journal of Medicine 2014). Recent data indicates that there is a significant overlap of molecular subtypes of breast cancer and bladder cancer (BC). The aim of the present study was to evaluate the performance of a CTC platform designed for PCR based characterization of breast cancer CTCs (Adnatest©) in a cohort of patients with different stages of BC. METHODS We included an equally distributed selective cohort of 29 control patients without BC, 30 patients with non-muscle invasive BC (NMIBC), 21 patients with muscle invasive BC (MIBC) and 26 patients with metastatic BC. EpCAM, EGFR or HER-2 positive cells were isolated by immunomagnetic enrichment and processed by RNA isolation, reverse transcription and PCR for breast cancer specific transcripts (MUC1, HER2), markers of epithelial mesenchymal transition (EMT) and ALDH1, a marker characteristic for basal breast cancer and cancer stem cells. RESULTS Transcripts of MUC1 or HER2 were detected in 3.4%, 6.7%, 14.3% and 19.3% of patients with no BC, NMIBC, MIBC and metastatic BC. In patients with MIBC, MUC1/HER2 transcripts were present in 0.0% of patients with organ-confined disease and 25.0% of patients with locally advanced disease. Transcripts of ALDH1 were detected in 10.3%, 10.0%, 28.6% and 34.6% of patients with no BC, NMIBC, MIBC and metastatic BC. In the group of patients with organ-confined MIBC, 11.1% were positive for ALDH1 vs. 41.7% in patients with locally advanced MIBC. CONCLUSIONS A PCR-based platform designed for characterization of circulating breast cancer cells provides promising performance in patients with BC. Detection rates of cancer specific transcripts clearly correlated with stage of disease. Moreover, the proportion of patients with CTCs expressing markers of cancer stem cells and basal like breast cancer increases during progression of disease. Whether the use of this platform may help to identify patients with different molecular subtypes of BC to predict response to chemotherapy remains to be elucidated. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e844 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Tilman Todenhöfer More articles by this author Jörg Hennenlotter More articles by this author Natalie Dorner More articles by this author Gunthild Beger More articles by this author Valentina Gerber More articles by this author Georgios Gakis More articles by this author Simone Bier More articles by this author Steffen Rausch More articles by this author Johannes Mischinger More articles by this author Stefan Aufderklamm More articles by this author Natalie Feniuk More articles by this author Doreen Schellbach More articles by this author Arnulf Stenzl More articles by this author Christian Schwentner More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...